Diffuse Large B Cell Lymphoma: Five Factors For A Prognosis

Diffuse large B cell lymphoma prognosis is contingent upon several factors, and can be determined by using a well-established and reliably predictive model known as the Revised International Non-Hodgkin's Lymphoma Prognostic Index (IPI or R-IPI). In order for this to be applicable, the patient must have been diagnosed with DLBCL and be treated with Rituximab-based combination chemotherapy, namely R-CHOP.

The Index uses five factors for a prognosis, assigns a single point to each factor if true, then takes the sum total and uses it to determine a survival rate percentage.

Prognosis Factors

  • AGE: Patients over the age of 60 add one point.
  • SERUM LDH: If LDH (lactate dehydrogenase) levels are elevated, add one point.
  • PERFORMANCE STATUS: If the patient's performance status is determined to be between 2 and 4 add one point.
  • DISEASE STAGE: If the patient is diagnosed at stage III or stage IV, add one point.
  • EXTRANODAL INVOLVEMENT: If the patient's lymphoma involves more than one extranodal site (such as bone, liver, spleen, or bone marrow), add one point.

So a patient can have between 0 and 5 points. Here's what those totals mean for a prognosis:

0 points

  • Prognosis: Very good
  • Predicted 4-year progression-free survival: 94 percent
  • Overall survival: 94 percent

1-2 points

  • Prognosis: Good.
  • Predicted 4-year progression-free survival: 80 percent
  • Overall survival: 79 percent

3-5 points

  • Prognosis: Poor
  • Predicted 4-year progression-free survival:53 percent
  • Overall survival: 55 percent

Conclusion

This index has shown to be a reasonably predictive model in determining a prognosis; however, it will not hold true for every single diagnosed and treated patient.

Related Reading

Photo: Pexels

More Articles

More Articles

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...

Diagnosing lymphoma is one of the more difficult diagnoses to make in cancer medicine, and contrary to perception, diagnosing lymphoma is not made...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Follicular lymphoma is classified as a Non-Hodgkin's Lymphoma. It is an indolent (slow-growing) cancer that affects...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

Lymphoma is not difficult to diagnose once a patient and doctor begin to look for signs of cancer. However, Lymphoma–especially...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

The lymphatic system, or lymph system, defends the body from foreign invasion by disease causing agents such as viruses, bacteria, or fungi. The...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

With any cancer, early detection is the best predictor of long-term survival, and lymphoma is no exception. The trickiest thing about lymphoma is...